ACE Inhibitor-induced angioedema

Monali Vasekar; Timothy J. Craig

doi:10.1007/s11882-011-0238-z

ACE Inhibitor-induced angioedema

Monali Vasekar, Timothy J. Craig

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

Original language	English (US)
Pages (from-to)	72-78
Number of pages	7
Journal	Current Allergy and Asthma Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1007/s11882-011-0238-z
State	Published - Feb 2012

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1007/s11882-011-0238-z

Cite this

@article{ee0ae0684b5046eeb88bf45f8e8a440f,

title = "ACE Inhibitor-induced angioedema",

abstract = "Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.",

author = "Monali Vasekar and Craig, {Timothy J.}",

year = "2012",

month = feb,

doi = "10.1007/s11882-011-0238-z",

language = "English (US)",

volume = "12",

pages = "72--78",

journal = "Current Allergy and Asthma Reports",

issn = "1529-7322",

publisher = "Current Medicine Group",

number = "1",

}

TY - JOUR

T1 - ACE Inhibitor-induced angioedema

AU - Vasekar, Monali

AU - Craig, Timothy J.

PY - 2012/2

Y1 - 2012/2

N2 - Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

AB - Much has been written about hereditary angioedema (HAE) in recent literature; however, the prevalence of angiotensin-converting enzyme inhibitor-induced angioedema (ACEiIA) far exceeds that of HAE. Similarly, multiple therapies have been developed for HAE, yet no definitive therapy is available for ACEiIA. In this article, we discuss the mechanism, prevalence, pathophysiology, and management of ACEiIA, with focus on newer therapies recently approved for HAE and how they may be effective for ACEiIA.

UR - http://www.scopus.com/inward/record.url?scp=84857627080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857627080&partnerID=8YFLogxK

U2 - 10.1007/s11882-011-0238-z

DO - 10.1007/s11882-011-0238-z

M3 - Article

C2 - 22127615

AN - SCOPUS:84857627080

SN - 1529-7322

VL - 12

SP - 72

EP - 78

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

IS - 1

ER -

ACE Inhibitor-induced angioedema

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this